Clinical Trials
130 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
RABBIT
University of Arizona
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
iCaRe2
University of Nebraska
Evaluation for NCI Surgery Branch Clinical Research Protocols
National Institutes of Health Clinical Center (CC)
DP-04
AstraZeneca
ELEPHAS-02
Elephas
CER
Cancer Support Community, Research and Training Institute, Philadelphia
TraveraRTGx
Travera Inc
PRESERVE-009
OncoC4, Inc.
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Memorial Sloan Kettering Cancer Center
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
EBNK-ST-001
Essen Biotech
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
ELEPHAS-05
Elephas
ON-5001
OncoNano Medicine, Inc.
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
DETERMINE
Cancer Research UK
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
AYAConnect
UNC Lineberger Comprehensive Cancer Center
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
AGADIR
Institut Bergonié
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
EARN
Washington University School of Medicine
ORACLE
Guardant Health, Inc.
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
DELFI-L101
Delfi Diagnostics Inc.
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
ABILITY-1
Medicenna Therapeutics, Inc.
START-001
Marengo Therapeutics, Inc.
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.